Know Cancer

forgot password

A Open Label Phase II Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression

Phase 2
18 Years
Open (Enrolling)
Ovarian Epithelial Carcinoma

Thank you

Trial Information

A Open Label Phase II Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression

Inclusion Criteria

Inclusion Criteria

1. Histologically-confirmed ovarian epithelial (including fallopian tube and primary
peritoneal) carcinoma.

2. Baseline paraffin embedded tissue from the patient's primary diagnosis is requested
before study enrolment and should be forwarded to the designated central laboratory
where central assessment of Rb and p16 expression will be performed by using
immunohistochemistry. In patients with measurable disease a tissue biopsy may be
obtained by core biopsy and submitted to the designated central laboratory. Only
patients with a tumor specimen demonstrating absent or low p16 expression and
Rb-proficiency will be eligible.

3. GCIG-defined CA125 progression and absence of disease upon imaging or small-volume
asymptomatic disease upon imaging and who have progressed following one, two or three
lines of chemotherapy for recurrent disease.

4. If patients have small-volume disease the current study will be restricted to
patients with minimal ascites not causing abdominal distention/mesenteric thickening
or not requiring paracentesis, or lesions ≤4 cm by spiral computed tomography [CT] or
magnetic resonance imaging [MRI] at baseline.

5. Two pretreatment CA125 values (documented on two occasions taken at least one week
apart) must be at least twice the upper limit of normal, or twice the nadir value if
pretreatment CA125 values never normalized.

6. Patients with platinum-sensitive or platinum-resistant disease defined by recurrence
or progression of disease > 6 months or ≤ than 6 months after completion of frontline
platinum based chemotherapy.

7. ECOG performance status ≤ 1 and patients are to be ≥21 years of age.

8. Resolution of any toxic effects of prior therapy (except alopecia) to NCI CTCAE v.3.0
Grade ≤ 1 and to baseline laboratory values as defined in the inclusion criterion
immediately below.

9. Adequate organ and bone marrow function as evidenced by:

- hemoglobin ≥ 9.0 g/dL

- absolute neutrophil count ≥ 1.5 x 109/L

- platelet count ≥ 100 x 109/L

- Renal function, as follows:

- Serum creatinine ≤ 1.5 x the ULN or calculated creatinine clearance ≥ 40 mL/min

- AST and ALT ≤ 2.5 x ULN

- total bilirubin ≤ 1.5 x ULN unless increase is due to Gilbert's disease or
similar syndrome involving slow conjugation of bilirubin,

10. Adequate coagulation parameters (within 21 days prior to registration), International
Normalized Ratio (INR) ≤1.5; Activated ProThrombin Time (APTT) ≤ 1.5 x ULN.

11. Patient must be willing and able to comply with scheduled visits, treatment plans,
laboratory tests, and other study procedures.

12. Informed consent must be obtained in writing for all patients prior to performing
study/screening procedures and prior to registration into the study.

Exclusion Criteria

Patients presenting with any of the following will not be included in the study:

1. More than 4 prior chemotherapy regimens in the treatment of ovarian cancer.

2. Anticipation of immediate need for a major surgical procedure (e.g., impending bowel
obstruction, gastrointestinal perforation) or radiation therapy during the trial.

3. Diagnosis of any second malignancy within the last 5 years, except for adequately
treated basal cell or squamous cell skin cancer, or for in situ carcinoma of the
cervix uteri or breast.

4. Treatment with chemotherapy, radiotherapy, surgery, blood products, or an
investigational agent within 3 weeks of trial enrolment.

5. Any of the following within 6 months prior to trial registration: myocardial
infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft,
NYHA class III or IV congestive heart failure, cerebrovascular accident or transient
ischemic attack, pulmonary embolism, deep vein thrombosis, or other thromboembolic
event. PD0332991 in Recurrent Ovarian Cancer

6. History of brain metastases, spinal cord compression, or carcinomatous meningitis.

7. Patient of child-bearing potential is evidently pregnant (eg, positive human
chorionic gonadotropin test) or is breast feeding. A woman with child bearing
potential is defined as not surgically sterile or being post-menopausal for less than
6 months.

8. Patient of child-bearing potential is not willing to use adequate contraceptive
precautions. Adequate effective method of contraception are those which result in low
failure rates, less than 1% per year, such as non-hormonal IUD, condoms, sexual
abstinence or vasectomised partner.

9. Known active infection, or on antiretroviral therapy for HIV disease or positive test
for chronic hepatitis B or C infection.

10. Mental condition rendering the patient unable to understand the nature, scope, and
possible consequences of the trial.

11. Refusal or inability to give informed consent to participate in the trial.

12. Corrected QT (QTc) interval >470 msec.

13. If radiotherapy is required in a given patient, that patient should be withdrawn from
the study.

14. Current use or anticipated need for: Food or drugs that are known strong CYP3A4
inhibitors (i.e. grapefruit juice, verapamil, ketoconazole, miconazole, itraconazole,
posaconazole, erythromycin, clarithromycin, telithromycin, indinavir, saquinavir,
ritonavir, nelfinavir, lopinavir, atazanavir, amprenavir, fosamprenavir, nefazodone,
diltiazem, and delavirdine.

15. Other severe acute or chronic medical or psychiatric condition, or significant
laboratory abnormality requiring further investigation that may cause undue risk for
the patient's safety, inhibit protocol participation, or interfere with
interpretation of trial results, and in the judgment of the investigator would make
the patient inappropriate for entry into this trial.

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Estimate biochemical response rate as determined by CA125 response using the Gynecologic Cancer Intergroup (GCIG) response criteria of PD0332991 in patients with recurrent ovarian epithelial carcinoma.

Outcome Description:

CA125 response is defined as ≥ 50% decrease from the baseline CA125 level and confirmed ≥ 21 days after initial evaluation (baseline is defined as the higher value of 2 pre-treatment CA125 assessments).

Outcome Time Frame:

4 weeks

Safety Issue:


Principal Investigator

Gottfried Konecny, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Jonsson Comprehensive Cancer Center


United States: Food and Drug Administration

Study ID:




Start Date:

December 2011

Completion Date:

Related Keywords:

  • Ovarian Epithelial Carcinoma
  • Carcinoma
  • Ovarian Neoplasms
  • Neoplasms, Glandular and Epithelial



Jonsson Comprehensive Cancer Center at UCLALos Angeles, California  90095-1781